Eli Lilly launches Mounjaro in India at about $50 a vial, beating Novo Nordisk

Eli Lilly launched Mounjaro, its tirzepatide injection for type 2 diabetes and weight loss, in India on March 20, 2025, getting to the market ahead of rival Novo Nordisk ^[1]. India's drug regulator had approved the drug, and Lilly began selling it there in two vial strengths ^[1][2].

Lilly told Reuters the 5 mg vial is priced at 4,375 rupees, or $50.67, and the 2.5 mg vial at 3,500 rupees, or $40.54. Its highest dose is 15 mg ^[1]. A patient taking a weekly 5 mg dose could spend about $200 a month, depending on the prescription ^[1]. Doses sold at launch were 2.5 mg and 5 mg vials ^[2].

Vishal Manchanda, an analyst at Systematix Institutional Equities, said the launch gives Lilly a first-mover advantage but called the pricing high for India, estimating that a patient on the highest dose would spend close to 700,000 rupees, around $8,100, per year ^[1].

By comparison, Mounjaro carries a US list price of $1,086.37 for a monthly fill, though what patients pay depends largely on insurance ^[1]. Lilly also sells Zepbound, its tirzepatide brand for obesity in the US, in 5 mg, 7.5 mg and 10 mg vials at around $499 for a month's supply for customers paying cash directly ^[1]. Lilly said pricing in different countries cannot be compared because health systems, economies and reimbursement policies vary ^[1].

Novo Nordisk's Wegovy, which contains semaglutide, had already been approved in India at the time of Lilly's launch, but Novo said it had no confirmed date for the Indian launch ^[1]. Internal pressure went the other way: Novo's India team had been urging the company's leadership to launch Wegovy as early as 2025 rather than its 2026 target ^[1]. Novo launched Wegovy in India on June 24, 2025, three months after Lilly began marketing Mounjaro there ^[2]. On June 26, 2025, India's Central Drugs Standard Control Organization approved the Mounjaro KwikPen, a pre-filled injector for once-weekly use, in six strengths from 2.5 mg to 15 mg ^[2].

India's market is large and growing. The number of Indian adults with diabetes is projected to rise to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation, and a government survey from 2019 to 2021 found 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19% in 2015-2016 ^[1]. The World Obesity Federation Atlas projects that about 11% of Indian adults will be obese by 2035 ^[2].

Lilly's launch is also drawing generic competition. Semaglutide, the ingredient in Wegovy and Ozempic, is likely to go off patent in India in 2026 ^[1][2]. Sun Pharma is developing its own GLP-1, utreglutide, and has said it expects to launch in four to five years; Biocon, Zydus Lifesciences, Cipla, Dr. Reddy's and Lupin are among the Indian companies working on versions of semaglutide ^[2]. Media reports, which Reuters said it could not independently verify, also name Natco Pharma, Mankind Pharma and Aurobindo Pharma as developing cheaper versions of Wegovy ^[2]. One estimate cited by Reuters put the global market for these drugs at $150 billion over the next decade ^[1].

Why it matters for patients

Prices set for India do not set prices in the United States. Lilly said the figures from different countries cannot be compared, and US pricing runs through insurers, pharmacy benefit managers and Lilly's own cash-pay programs ^[1]. Nothing in the Indian launch changes the US list price of $1,086.37 per monthly fill for Mounjaro or the roughly $499 cash price for Zepbound vials ^[1].

The bigger long-term question for US patients is supply and competition. Novo Nordisk and Lilly have both seen heavy global demand, and the arrival of semaglutide generics in India after patent expiry there is expected to add supply in that country ^[1][2]. Whether that affects availability or pricing in the US has not been established. Lilly has said it plans to launch Mounjaro in more markets this year, but it has not said which ones ^[1].

What happens next

Novo launched Wegovy in India on June 24, 2025, and Lilly's Mounjaro KwikPen was approved there on June 26, 2025 ^[2]. The semaglutide patent is expected to expire in India in 2026, which is when several Indian manufacturers plan to bring generic versions to market ^[1][2]. Sun Pharma has said its utreglutide is four to five years away ^[2]. Sales figures for Mounjaro in India have not been disclosed in these accounts.